Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target
- 1 September 2015
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 95 (5) , 589-598
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trialThe Lancet, 2012
- New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]The International Journal of Tuberculosis and Lung Disease, 2012
- Exploiting bacterial DNA gyrase as a drug target: current state and perspectivesApplied Microbiology and Biotechnology, 2011
- New Alkaloid Antibiotics That Target the DNA Topoisomerase I of Streptococcus pneumoniaeJournal of Biological Chemistry, 2011
- DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsChemistry & Biology, 2010
- Structure and mechanism of action of type IA DNA topoisomerasesBiochemistry (Moscow), 2009
- Multidrug-resistant and extensively drug-resistant tuberculosis: a reviewCurrent Opinion in Infectious Diseases, 2008
- Bacterial topoisomerase I as a target for discovery of antibacterial compoundsNucleic Acids Research, 2008
- The creation of a camptothecin-sensitive Escherichia coli based on the expression of the human topoisomerase IGene, 1995
- Isolation and characterization of a topA mutant of Shigella flexneriMolecular Microbiology, 1993